Literature DB >> 9301992

Norfloxacin resistance in Campylobacter jejuni and Campylobacter coli isolates from Swedish patients.

E Sjögren1, G B Lindblom, B Kaijser.   

Abstract

This study focused on the frequency of Campylobacter jejuni and Campylobacter coli strains resistant to norfloxacin. Included were 1659 consecutive stool specimens isolated between 1992 and 1995, from as many Swedish patients with diarrhoea. The patients were divided with regard to place of infection and age. All strains were tested for susceptibility to norfloxacin by means of disc diffusion test on blood-agar plates. Norfloxacin-resistant strains (n = 310) were furthermore tested for resistance to doxycycline and erythromycin. The Etest was used for determination of MIC values of doxycyclin, erythromycin and norfloxacin of 81 of the strains. C. jejuni and C. coli isolations resistant to norfloxacin were significantly more frequent among patients infected abroad, especially in Spain and Thailand, compared with those infected in Sweden, adults more often than children. The number of resistant strains showed a yearly increase, and the difference between children and adults was equalized in 1995. The MIC50 and MIC90 values for doxycycline and erythromycin have increased markedly through the 4 years studied. This study shows that norfloxacin, because of increased resistance, may have limited utility for treatment of gastrointestinal infections caused by C. jejuni and C. coli.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9301992     DOI: 10.1093/jac/40.2.257

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.

Authors:  Jutta Wagner; Miriam Jabbusch; Martin Eisenblätter; Helmut Hahn; Constanze Wendt; Ralf Ignatius
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

2.  gyrA polymorphism in Campylobacter jejuni: detection of gyrA mutations in 162 C. jejuni isolates by single-strand conformation polymorphism and DNA sequencing.

Authors:  Antti Hakanen; Jari Jalava; Pirkko Kotilainen; Hannele Jousimies-Somer; Anja Siitonen; Pentti Huovinen
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

3.  Antimicrobial-resistant Campylobacter species from retail raw meats.

Authors:  Beilei Ge; David G White; Patrick F McDermott; Webb Girard; Shaohua Zhao; Susannan Hubert; Jianghong Meng
Journal:  Appl Environ Microbiol       Date:  2003-05       Impact factor: 4.792

4.  Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates.

Authors:  J Engberg; F M Aarestrup; D E Taylor; P Gerner-Smidt; I Nachamkin
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

5.  Rapid emergence of high-level resistance to quinolones in Campylobacter jejuni associated with mutational changes in gyrA and parC.

Authors:  A Gibreel; E Sjögren; B Kaijser; B Wretlind; O Sköld
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

6.  Activities of telithromycin, erythromycin, fluoroquinolones, and doxycycline against Campylobacter strains isolated from Finnish subjects.

Authors:  Daniela Schönberg-Norio; Marja-Liisa Hänninen; Marja-Leena Katila; Suvi-Sirkku Kaukoranta; Markku Koskela; Erkki Eerola; Jaakko Uksila; Sini Pajarre; Hilpi Rautelin
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

7.  Antimicrobial susceptibilities of Campylobacter strains isolated from Finnish subjects infected domestically or from those infected abroad.

Authors:  Hilpi Rautelin; Antti Vierikko; Marja-Liisa Hänninen; Martti Vaara
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

8.  Antibiotic Resistance of Campylobacter Species in a Pediatric Cohort Study.

Authors:  Francesca Schiaffino; Josh M Colston; Maribel Paredes-Olortegui; Ruthly François; Nora Pisanic; Rosa Burga; Pablo Peñataro-Yori; Margaret N Kosek
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

9.  Quinolone-resistant Campylobacter infections: risk factors and clinical consequences.

Authors:  Jørgen Engberg; Jakob Neimann; Eva Møller Nielsen; Frank Møller Aerestrup; Vivian Fussing
Journal:  Emerg Infect Dis       Date:  2004-06       Impact factor: 6.883

Review 10.  Antimicrobial resistance mechanisms among Campylobacter.

Authors:  Kinga Wieczorek; Jacek Osek
Journal:  Biomed Res Int       Date:  2013-06-24       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.